- The Canadian Competition Bureau is investigating Cigna's Express Scripts for alleged anti-competitive practices.
- Wall Street analysts forecast an upside potential for Cigna Group's stock.
- GuruFocus' GF Value projects significant growth for Cigna Group in the next year.
The Canadian Competition Bureau has launched an investigation into Cigna's (CI, Financial) Express Scripts unit. The inquiry revolves around accusations of anti-competitive practices within Canada's drug retail market. Specific allegations point to the company's efforts to steer patients towards its own pharmacies and compress the margins for retail pharmacies. As part of the investigation, Express Scripts is mandated to provide evidence to the authorities.
Wall Street Analysts: Positive Forecast for Cigna
With 23 analysts weighing in, the average one-year price target for The Cigna Group (CI, Financial) stands at $359.83. Their projections range from a high of $395.00 to a low of $323.00. This average target price suggests a potential upside of 9.23% from the current trading price of $329.44. For more detailed estimates, please visit the The Cigna Group (CI) Forecast page.
Brokerage Recommendations Indicate "Outperform"
Consensus from 26 brokerage firms positions The Cigna Group's (CI, Financial) average brokerage recommendation at 2.0, denoting an "Outperform" status. This rating is based on a scale from 1 to 5, where 1 represents a Strong Buy and 5 stands for Sell, indicating an overall positive outlook from analysts.
GuruFocus GF Value Estimates Substantial Upside
According to GuruFocus' GF Value, The Cigna Group's stock is estimated to be valued at $445.56 in one year. This projection presents a notable upside potential of 35.25% from the current price of $329.44. The GF Value is determined by analyzing historical trading multiples, past business growth, and future business performance estimates. More comprehensive data is available on the The Cigna Group (CI, Financial) Summary page.
